Glimigard-M2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, designed for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic regulation without causing significant weight gain. The sustained-release formulation allows for a gradual release of active ingredients, minimizing gastrointestinal side effects commonly associated with Metformin and improving patient compliance through once or twice daily dosing. Glimigard-M2 is indicated as an adjunct to diet and exercise for patients inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor renal function prior to initiation and periodically thereafter, as Metformin is contraindicated in patients with significant renal impairment. Caution is advised to avoid hypoglycemia, particularly when combined with other antidiabetic agents or in patients with irregular meal patterns. Overall, Glimigard-M2 Tablet SR offers a synergistic approach to managing hyperglycemia in type 2 diabetes, enhancing both insulin secretion and sensitivity to achieve effective glycemic control.